Thus, we hypothesise that pre‐treatment of hosts either with HDAC‐inhibitors or CGRPs will synergise with CAR‐T cells in targeting IL‐13Rα2 positive solid cancer for a better anti‐ tumour effect. This evidence concerns the gene IL13RA2 and neoplasm.